What is the generic name?

VANCOMYCIN HYDROCHLORIDE

What is the Trade Name for VANCOMYCIN HYDROCHLORIDE?

FIRVANQ

What are the Indications for VANCOMYCIN HYDROCHLORIDE?

• 1 INDICATIONS AND USAGE FIRVANQ is indicated for the treatment of Clostridium difficil e‚Äëassociated diarrhea in adults and pediatric patients less than 18 years of age. FIRVANQ is also indicated for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin‚Äëresistant strains) in adults and pediatric patients less than 18 years of age. Important Limitations of Use ‚Ä¢ Parenteral administration of vancomycin is not effective for the above infections; therefore, vancomycin must be given orally for these infections. ‚Ä¢ Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections. To reduce the development of drug‚Äëresistant bacteria and maintain the effectiveness of FIRVANQ and other antibacterial drugs, FIRVANQ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. FIRVANQ is a glycopeptide antibacterial indicated in adults and pediatric patients less than 18 years of age for the treatment of: ( 1 ) ‚Ä¢ Clostridium difficile ‚Äëassociated diarrhea ‚Ä¢ Enterocolitis caused by Staphylococcus aureus (including methicillin‚Äëresistant strains) Important Limitations of Use: ( 1 ) ( 5.1 ) ‚Ä¢ Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections. To reduce the development of drug‚Äëresistant bacteria and maintain the effectiveness of FIRVANQ and other antibacterial drugs, FIRVANQ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1 )

References: https://open.fda.gov/